Ironwood Pharmaceuticals Inc

IRWD remains in a Stage 4 decline with confirmed lower highs and lower lows under a bearish EMA regime. Price is trading below the down-sloping 9 and 21 EMAs and is now pulling back toward the 50 DMA without evidence of selling exhaustion or stabilization. The medium-term bias is bearish, permitting only sell-side engagement. Execution should focus on Sell Now into rallies to the 9/21 EMA resistance and recent horizontal levels.

• ↑Linzess net sales $272.5m in Q1 2026, up 97% YoY.
• ↑Apraglutide Phase 3 STARS-2 trial underway; peak sales forecast >$1B.
• ↓Profitability under pressure from pricing cuts and rising costs.